Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 7/20 | 0.69 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CYBB | P04839 | 2/20 | 0.45 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 0.45 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219755 | 0.85 | NOX4 (0.54) | NOX4MCHR1KCNH2HRH3CYBB | |
| SCHEMBL2219544 | 0.83 | NOX4 (0.72) | NOX4MCHR1KCNH2CYBBNPC1 | |
| SCHEMBL2218953 | 0.83 | NOX4 (0.58) | NOX4MCHR1KCNH2HRH3CYBB | |
| SCHEMBL1303175 | 0.82 | NOX4 (1.00) | NOX4MCHR1KCNH2CYBBNPC1 | |
| SCHEMBL2217532 | 0.81 | NOX4 (0.50) | NOX4HRH3CYBBNOX5NOX1 | |
| SCHEMBL2218198 | 0.77 | NOX4 (0.64) | NOX4CYBBNOX5NOX1 | |
| SCHEMBL1302779 | 0.75 | NOX4 (0.62) | NOX4MCHR1HTTCYBBNOX1 | |
| SCHEMBL19956763 | 0.74 | NOX4 (0.75) | NOX4CYBBKDM4ENPC1RAB9A | |
| SCHEMBL2219961 | 0.73 | NOX4 (0.60) | NOX4MCHR1KCNH2CYBB | |
| SCHEMBL1302232 | 0.72 | NOX4 (0.68) | NOX4CYBBNOX5NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | claimed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | claimed |
| EP-2674160-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2013-12-18 | — | — | EP | claimed |
| EP-2349261-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-08-14 | — | — | EP | claimed |
| US-20130143879-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-06-06 | — | — | US | claimed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | claimed |
| EP-2349261-A2 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-08-03 | — | — | EP | claimed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | claimed |
| WO-2010035219-A2 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | claimed |
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143879-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885MCHR1 4578/4885KCNH2 2221/4885 |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885MCHR1 4578/4885KCNH2 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.